Colorectal cancer therapies market remains constant at $ 7.7 billion by 2023

Colorectal cancer therapies market remains constant at $ 7.7 billion by 2023 -

Decision Resources Group believes that the market for colorectal cancer (CRC) remains therapies constant at about 7.7 billion $ 2023 in the US, France, Germany, Italy, Spain, UK and Japan. The biosimilar erosion of Avastin and Roche / Genentech / Chugai Bristol-Myers Squibb / Eli Lilly / Erbitux from Merck KGaA will be offset by the launch of Cyramza Eli Lilly, Lonsurf Taiho Pharmaceutical, HA-Irinotecan and vargatef Boehringer Ingelheim of Alchemia and increased absorption of Zaltrap Sanofi / Regeneron and Vectibix from Amgen / Takeda

Other key findings of the report entitled Pharmacor colorectal cancer :.

• impact of RAS trials of EGFR inhibitors: [1945009 RAS [] extended test [1945005limiteralapopulationglobaledespatientsadmissiblesàrecevoirlerécepteurdufacteur(EGFR)lesinhibiteursdecroissanceépidermiqueCependantonprévoitquel'inhibiteurdel'EGFRdepremièrelignedeprescriptionpouraugmenterenraisondesdonnéesdesCALGB80405FIRE-3etPEAKessaismontrantunbénéficedesurviepourlesinhibiteursdel'EGFRdansdetypesauvage RAS patients.
• Increased competition between angiogenesis inhibitors in the second line on: Prescribing of Zaltrap in the second-line setting was negatively impacted by the extension of the Avastin label allowing its use beyond progression frontline. With the expected launch of Cyramza under second line, competition is expected to increase in this context
• treatment options increased in subsequent adjustments line :. The recent launch of Stivarga Bayer HealthCare gave patients an additional option of further processing line. Patients will have a wider range of treatment options with planned launches Lonsurf and vargatef.

Comments Decision Resources Group analyst Dan Roberts, Ph.D.:

• "Although the introduction of RAS test extended will decrease eligible population who ultimately receive these drugs, there will be a slight increase in the number of patients receiving the inhibition of EGFR as a first-line treatment. "
• "colorectal cancer market already has five approved targeted agents, with more being launched during the forecast period. With so many choices, doctors will struggle to determine what sequence of therapies is best for their patients. "